drugset / Trial / NCT05457517
A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a one-arm, open, multicenter phase 1b/2 clinical trial of YL-13027 combined with Sintilimab in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D and observing the preliminary efficacy.The trial can be divided into two parts: dose escalation part and expansion part.Sintilimab is administered as a fixed-dose intravenous injection(200mgQ3w）.
Timeline
- Start
- 2022-09-24
- Primary completion
- 2024-06-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |
| Subject | YL-13027 | Small molecule | 240 mg | Oral |
| Subject | YL-13027 | Small molecule | 360 mg | Oral |